Dual-Plane Treatment With Highly Concentrated Hybrid Cooperative Complexes of Hyaluronans for Facial Atrophic Acne Scars.

IF 2.5 3区医学 Q2 DERMATOLOGY Dermatologic Surgery Pub Date : 2024-10-04 DOI:10.1097/DSS.0000000000004387

Adele Sparavigna, Franco Grimolizzi, Clara Cigni, Roberto Lualdi, Gilberto Bellia

{"title":"Dual-Plane Treatment With Highly Concentrated Hybrid Cooperative Complexes of Hyaluronans for Facial Atrophic Acne Scars.","authors":"Adele Sparavigna, Franco Grimolizzi, Clara Cigni, Roberto Lualdi, Gilberto Bellia","doi":"10.1097/DSS.0000000000004387","DOIUrl":null,"url":null,"abstract":"Background: Managing patients with acne scars remains an important challenge, as scarring negatively affects psychosocial wellbeing. Hyaluronic acid (HA) cross-linked fillers have demonstrated good efficacy and tolerability for the correction of acne scars but are limited by their reduced biological activity and low concentrations.Objective: This study investigated the efficacy and safety on scars of a high-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC) of high-molecular-weight and low-molecular-weight HA.Methods: Participants received treatment twice; the first was provided at baseline (T0) and the second after 4 weeks (T1). Data were collected at T1 and after 4 months (T2) by photographs and instrumental evaluation of the skin.Results: The study population included 28 patients. Improvements in the mean Goodman and Baron grade were significant across time points T0 and T1 (12% improvement; p = .0002) and T0 and T2 (31% improvement; p < .0001). Instrumental evaluation of the skin surface demonstrated a 20% reduction in the average deepness of acne scars after 4 months (p < .0001). No serious adverse events were reported during the study procedure.Conclusion: Highly concentrated (4.5%) HCC appears to be an effective option for the correction of facial acne scars.","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000004387","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Managing patients with acne scars remains an important challenge, as scarring negatively affects psychosocial wellbeing. Hyaluronic acid (HA) cross-linked fillers have demonstrated good efficacy and tolerability for the correction of acne scars but are limited by their reduced biological activity and low concentrations.

Objective: This study investigated the efficacy and safety on scars of a high-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC) of high-molecular-weight and low-molecular-weight HA.

Methods: Participants received treatment twice; the first was provided at baseline (T0) and the second after 4 weeks (T1). Data were collected at T1 and after 4 months (T2) by photographs and instrumental evaluation of the skin.

Results: The study population included 28 patients. Improvements in the mean Goodman and Baron grade were significant across time points T0 and T1 (12% improvement; p = .0002) and T0 and T2 (31% improvement; p < .0001). Instrumental evaluation of the skin surface demonstrated a 20% reduction in the average deepness of acne scars after 4 months (p < .0001). No serious adverse events were reported during the study procedure.

Conclusion: Highly concentrated (4.5%) HCC appears to be an effective option for the correction of facial acne scars.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用高浓度混合合作复合物透明质酸治疗面部萎缩性痤疮疤痕。

背景：管理痤疮疤痕患者仍是一项重要挑战，因为疤痕会对社会心理健康产生负面影响。透明质酸（HA）交联填充剂在矫正痤疮疤痕方面具有良好的疗效和耐受性，但因其生物活性降低和浓度低而受到限制：本研究调查了高浓度（4.5%）HA填充剂与高分子量和低分子量HA混合协同复合物（HCC）对疤痕的疗效和安全性：参与者接受两次治疗；第一次在基线（T0）时，第二次在 4 周后（T1）。在 T1 和 4 个月后（T2）通过照片和皮肤仪器评估收集数据：研究对象包括 28 名患者。在 T0 和 T1（改善 12%；p = 0.0002）以及 T0 和 T2（改善 31%；p < 0.0001）这两个时间点上，古德曼和巴隆等级的平均值均有显著改善。皮肤表面的仪器评估显示，4 个月后，痤疮疤痕的平均深度减少了 20%（p < .0001）。研究过程中未出现严重不良反应：高浓度（4.5%）HCC 似乎是矫正面部痤疮疤痕的有效选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatologic Surgery 医学-皮肤病学

CiteScore

3.10

自引率

16.70%

发文量

547

期刊介绍： Exclusively devoted to dermatologic surgery, the Dermatologic Surgery journal publishes the most clinically comprehensive and up-to-date information in its field. This unique monthly journal provides today’s most expansive and in-depth coverage of cosmetic and reconstructive skin surgery and skin cancer through peer-reviewed original articles, extensive illustrations, case reports, ongoing features, literature reviews and correspondence. The journal provides information on the latest scientific information for all types of dermatologic surgery including: -Ambulatory phlebectomy- Blepharoplasty- Body contouring- Chemical peels- Cryosurgery- Curettage and desiccation- Dermabrasion- Excision and closure- Flap Surgery- Grafting- Hair restoration surgery- Injectable neuromodulators- Laser surgery- Liposuction- Microdermabrasion- Microlipoinjection- Micropigmentation- Mohs micrographic surgery- Nail surgery- Phlebology- Sclerotherapy- Skin cancer surgery- Skin resurfacing- Soft-tissue fillers. Dermatologists, dermatologic surgeons, plastic surgeons, oculoplastic surgeons and facial plastic surgeons consider this a must-read publication for anyone in the field.